As­traZeneca lands FDA ap­proval for AKT in­hibitor in bio­mark­er-de­fined breast can­cer sub­set

As­traZeneca has scored an FDA ap­proval for its AKT in­hibitor capi­vasert­ib, adding a new tar­get­ed ther­a­py to its treat­ment of­fer­ings in breast can­cer.

The drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER